New research led by The University of Western Australia will lead to a world-first in testing strategy for penicillin allergy to ensure patients aren't avoiding taking antibiotics when they don't need to, as well as preventing more superbugs from emerging.
Lead author Clinical Professor Michaela Lucas, from UWA's Medical School, said researchers had found that up to 90 per cent of people reporting penicillin allergy may be avoiding the drug needlessly.
"What we found is that of those people who think they're highly allergic to penicillin; most actually have a very low risk of reaction, which means they may well tolerate some penicillin-based antibiotics. The next step is to support primary care providers to test those patients."
While protecting patients from medicine-related harm was the keystone of clinical care, the high rate of unverified antibiotic allergy was affecting the health of individual patients, Professor Lucas said.
"It's also contributing to the emergence of antimicrobial resistance via increased prescription of broad spectrum antibiotics," Professor Lucas said.
"This phenomenon is affecting populations globally. The vigilance of health professionals in protecting patients who self-report allergy is not currently accompanied by systems to verify allergy reports.
"And there is a lack of awareness that this is in fact resulting in harm to individuals and the health sector, which needs better testing strategies and communication tools to ensure correct drug avoidance advice in any clinical context."
Professor Lucas said self-reported allergy to penicillin was common and hospitals had alert (labelling) systems in place to prevent doctors prescribing penicillin to allergy sufferers.
"Working out who is truly allergic to penicillin usually requires a two-step process of skin-testing, and an oral 'challenge' supervised by hospital specialists," she said.
"This is necessary because current guidelines for testing don't take into consideration individual risk based on clinical history."
The research, published in the Journal of Allergy and Clinical Immunology: In Practice, used data from 447 Australian patient records, and statistical modelling, to define the minimal clinical criteria representing low-risk of reaction to the commonly prescribed antibiotic penicillin.
"This finding enables clinicians with limited drug allergy expertise, to select patients who can safely undergo penicillin allergy testing in primary care settings," Professor Lucas said.
"This approach is expected to lead to more efficient and lower cost service provision benefitting public health and the health sector."
